A third approved treatment is an epidermal growth factor (EGFR) inhibitor,
called erlotinib.
The team studied a lung cancer drug
called erlotinib which can be used to treat between 10 and 30 per cent of lung cancer patients.
Not exact matches
Approximately 10 - 15 % of Caucasian and 30 - 35 % of Asian patients with NSCLC have a mutation in the epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR inhibitors
called tyrosine kinase inhibitors (TKI), such as
erlotinib, gefitinib and afatinib.
They also analysed the patients» cancers for mutations in two other molecules, one
called EGFR which is the target of existing drugs gefitinib and
erlotinib, and another
called KRAS.